Immunologically modified MnFe2O4 nanoparticles to synergize photothermal therapy and immunotherapy for cancer treatment
Immunologically modified MnFe2O4 nanoparticles to synergize photothermal therapy and immunotherapy for cancer treatment
复制标题
免疫修饰的 MnFe2O4 纳米粒子协同光热疗法和免疫疗法治疗癌症
DOI：
10.1016/j.cej.2020.125239
复制
发表时间：
2020-09-15
影响因子：
15.1
通讯作者：
Chen, Wei R.
中科院分区：
文献类型：
--
作者：
Zhou, Benqing;Wu, Qiang;Chen, Wei R.
免疫疗法一直是癌症治疗的一种很有前途的候选方法。光热疗法(PTT)和免疫疗法的结合已经被证明可以导致肿瘤消融和诱导宿主免疫反应。然而，这一策略经常受到有限的免疫反应和不受欢迎的免疫抑制的阻碍。在这项工作中，我们开发了一种免疫修饰的纳米平台，将卵蛋白(OVA)包裹的聚乙二醇化MnFe2O4纳米颗粒(NPs)负载R837免疫佐剂(R837-OVA-PEG-MnFe2O4 NPs)，以协同PTT和免疫治疗治疗乳腺癌。所设计的R837-OVA-PEG-MnFe2O4纳米粒在体外和体内均能诱导显著的免疫应答。MnFe2O4纳米粒子还可以通过下调M2相关的细胞因子来减少全身免疫抑制。更重要的是，R837-OVA-PEGMnFe(2)O(4)纳米粒子在激光照射下有效地抑制了肿瘤生长，防止了肺转移，延长了生存时间，提高了存活率。此外，所设计的多任务MnFe2O4纳米粒子是一种理想的磁共振成像对比剂，可用于体内原位乳腺肿瘤的诊断。我们的工作为联合PTT和改进的免疫疗法治疗乳腺癌和其他转移性癌症提供了一种新的策略。
Immunotherapy has been a promising candidate for cancer treatment. The combination of photothermal therapy (PTT) and immunotherapy have shown to cause tumor ablation and induce host immune response. However, this strategy is often hampered by a limited immune response and undesirable immunosuppression. In this work, we developed an immunologically modified nanoplatform, using ovalbumin (OVA)-coated PEGylated MnFe2O4 nanoparticles (NPs) loaded with R837 immunoadjuvant (R837-OVA-PEG-MnFe2O4 NPs) to synergize PTT and immunotherapy for the treatment of breast cancer. The designed R837-OVA-PEG-MnFe2O4 NPs are able to elicit significant immune responses in vitro and in vivo. MnFe2O4 NPs also allowed for a reduction of systemic immunosuppression through downregulation of M2-associated cytokines. More importantly, the R837-OVA-PEGMnFe(2)O(4) NPs under laser irradiation effectively inhibited tumor growth and prevented lung metastases, leading to a prolonged survival time and improved survival rate. In addition, the designed multitasking MnFe2O4 NPs showed as a desirable contrast agent for magnetic resonance (MR) imaging to diagnose orthotopic breast tumor in vivo. Our work provides a novel strategy for combined PTT and improved immunotherapy in the treatment of breast and other metastatic cancers.